Ligand Pharmaceuticals (LGND +6.9%) gains today after reporting positive results from preclinical studies using its HepDirect liver-targeting technology platform for the treatment of hepatitis C. According to the data, LGND's HepDirect prodrug of 2'-C methylguanosine, LG-7501, may be effective in improving the effectiveness of hep C treatment while reducing systemic side effects.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs